智通财经APP讯,派林生物(000403.SZ)公告,公司全资子公司广东双林生物制药有限公司(称“广东双林”)收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.